Diagnostic criteria and severity assessment for syndesmosis injury using magnetic resonance imaging: A systematic review.

Foot Ankle SurgMay 6, 2026 (epub)
Clinical ResearchOrthopedic Surgery

Owen T Kennedy, Julia E Ralph, Alexander Hodakowski et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the diagnostic utility of magnetic resonance imaging (MRI) for syndesmosis injuries in 1931 ankles across 27 studies. MRI showed high diagnostic accuracy for complete tears of the anterior and posterior inferior tibiofibular ligaments. The review also identified ancillary signs that may assist in grading injury severity.

Key findings

  • MRI demonstrated high diagnostic accuracy for complete tears of the anterior and posterior inferior tibiofibular ligaments.
  • Ancillary signs like the ring-of-fire edema pattern showed high specificity for injury assessment.
  • Evidence gaps exist regarding the best parameters for determining injury severity in competitive athletes.

Why it matters

Accurate diagnosis and assessment of syndesmosis injuries are crucial for effective management and treatment planning. Understanding MRI's role can enhance clinical decision-making and improve patient outcomes.

Source

PubMed · PMID 42103548

Published in Foot Ankle Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.